Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis. (PubMed, J Gastroenterol) - Sep 29, 2026 - "Prior vedolizumab exposure was associated with lower ustekinumab effectiveness, suggesting that treatment history may be important when determining therapeutic sequencing in ulcerative colitis. Fibroblast-derived matrix metalloproteinase 13 represents a promising molecular marker associated with nonresponse to ustekinumab and may reflect an interleukin-1β-driven inflammatory fibroblast program linked to diminished treatment responsiveness."
Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL1B • MMP13
|
|
Akira Yamasaki; Cheng Pan; Hideaki Miyamoto; Hideaki Naoe; Hideki Kitada; Kana Omoto; Katsuya Nagaoka; Kenshi Matsuno; Koichi Sakurai; Kotaro Fukubayashi; Kotaro Waki; Masakuni Tateyama; Masatoshi Nakashima; Munenori Honda; Ryosuke Gushima; Shota Takano; Suguru Chiyonaga; Taichi Matsuyama; Takashi Shono; Takehisa Watanabe; Yasuhito Tanaka; Yoki Furuta; Yoshihiro Komohara; Yoshinari Sakai; Yuiko Tsuruta
|